Heart failure & cardiomyopathies
Effect of Mavacamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy: Insights From EXPLORER-HCM
Authors' conclusion
Although at baseline women with symptomatic obstructive HCM enrolled in EXPLORER-HCM were older and had worse heart failure and health status than men, treatment with mavacamten resulted in similar improvements in the primary and most secondary EXPLORER-HCM end points and greater improvements in health status and NT-proBNP.
Study context
- Population
- Symptomatic patients with obstructive hypertrophic cardiomyopathy (HCM)
- Participants
- 102 vs 149
- Comparison
- Mavacamten vs placebo, women vs men
- Womenn = 102
- Menn = 149reference
- Primary endpoint
- Primary composite end point
- Follow-up
- Week 30
Methodological detailsprespecified post hoc analysis of sex, blinded
- Prespecified post hoc analysis of sex
- Blinded
Primary result
As reported in the abstract
Primary composite end point (percentage difference mavacamten vs placebo) · 30 weeks
P = 0.759
Secondary outcomes
≥1 NYHA class improvement · 30 weeks
P = 0.254
| Outcome | Women | Men | P value |
|---|---|---|---|
| Change in postexercise LV outflow tract gradient · 30 weeks | −42.4 mm Hg | −33.6 mm Hg | P = 0.348 |
| Change in peak oxygen consumption · 30 weeks | 1.2 mL·kg-1·min-1 | 1.6 mL·kg-1·min-1 | P = 0.633 |
| Health status (KCCQ-Clinical Summary Score improvement) · 30 weeksGreater improvement in women | 14.8 | 6.1 | P = 0.026 |
| NT-proBNP change (exploratory) · 30 weeksGreater improvement in women · exploratory end point | −1322 ng/L | −649 ng/L | P = 0.0008 |
Original publication
Effect of Mavacamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy: Insights From EXPLORER-HCM. Circulation. Published 14 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →